Join
Live feed
·
PRReleasevia Quantisnow
Fulcrum Therapeutics Inc. logo
Sanofi logo

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

ByQuantisnow·Wall Street's wire, on your screen.
FULC· Fulcrum Therapeutics Inc.SNY· Sanofi
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FULC (Fulcrum Therapeutics Inc.), SNY (Sanofi) and more on Quantisnow.

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy | Quantisnow